Insights

In this episode of IBD Drive Time, Drs Millie Long and Raymond Cross talk to Dr Sara Horst about abstracts from the ECCO ’23 Congress on how best to utilize ozanimod to achieve optimum outcomes in inflammatory bowel disease.

Dr Cleveland, from the University of Chicago, reviews the use of intestinal ultrasound for the monitoring of inflammatory bowel disease and the significant advantages of this noninvasive, point-of-care technology for patients and clinicians...

S1Ps may work best for patients with moderate to more moderate-severe range of ulcerative colitis in the outpatient setting, particularly those earlier in their treatment journey, Dr Raymond Cross said during his presentation at the AIBD...

When used correctly and in a timely manner, biosimilars may increase access to important medications, such as the anti-tumor necrosis factor inhibitors for the treatment of IBD, Christina Ha, MD, explained at the AIBD regional meeting.

Drs Wallach and Rosenbaum discuss their study into the trends of IBD incidence among children in New York City during the COVID-19 pandemic, and their surprising findings.

Dr Adam Faye elaborates on how antibiotic exposure puts adults aged 40 years and older at an increased risk for developing inflammatory bowel disease.

In this episode of IBD Drive Time, Drs Millie Long and Raymond Cross talk with Dr Peter Higgins from the University of Michigan about the etiology of inflammatory bowel disease, including what is and what is not known, the hygiene hypothesis,...

Dr Long discusses her presentation at the Advances in Inflammatory Bowel Diseases regional meeting in Baltimore on the use of interleukin-12/23 and -23 inhibitors in the treatment of IBD.

Dr Cross, director of the IBD Program at the University of Maryland School of Medicine, discusses the key points from his presentation at the Advances in IBD regional meeting in Baltimore on using sphingosine 1-phosphate receptor modulators...